Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-583 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TAK-583 5 mg QD | EXPERIMENTAL | - |
| TAK-583 25 mg QD | EXPERIMENTAL | - |
| TAK-583 50 mg QD | EXPERIMENTAL | - |
| TAK-583 100 mg QD | EXPERIMENTAL | - |
| Placebo QD | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TAK-583 | DRUG | TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks |
| Placebo | DRUG | TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks |
Inclusion Criteria: * Male and female subjects with postherpetic neuralgia whose pain has been present for \>3 months following healing of the herpes zoster rash. * Subjects with an mean pain intensity score of 4 or more (determined from at least 4 daily recordings of pain intensity on an 11-point ...
TAK-583 is an investigational small molecule being studied for the treatment of diabetic neuropathies and postherpetic neuralgia, which are types of nerve pain. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
TAK-583 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Takeda's stock is listed on the New York Stock Exchange under the ticker symbol TAK.
TAK-583 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. Two Phase 2 trials have been completed, but the drug is not currently in active clinical trials.
TAK-583 has been studied in two completed Phase 2 trials. NCT00377598 evaluated the drug in 399 subjects with postherpetic neuralgia across multiple countries. NCT00760955 assessed its efficacy and safety in 338 subjects with diabetic peripheral neuropathy in the United States and Canada.
TAK-583 is a small molecule being investigated for its potential to treat nerve pain conditions. Its specific molecular target has not been disclosed in available information, so its exact mechanism of action is not publicly detailed.
No alternative names for TAK-583 have been disclosed. It is identified solely by its investigational code name TAK-583 in clinical trial registries and available data.